Huang Huang

Group Leader
Dana-Farber Cancer Institute

Huang obtained his PhD in Medicinal Chemistry at East China University of Science & Technology (2010-2015). Before his post-doc training on medicinal chemistry and chemical biology at University of Michigan Medical School (2016-2018), Huang worked at WUXI AppTec (2015-2016) as Senior Scientist providing synthesis service for Takeda. In 2018-2020, Huang worked at Silicon Therapeutics as investigator/senior investigator, and contributed to the research and development of STX-281, which is now in Phase I clinical trial. Currently, Huang is the Chemistry Group Leader of Center for Protein Degradation (CPD) at Dana-Farber Cancer Institute.